Tags

Type your tag names separated by a space and hit enter

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience.
Therap Adv Gastroenterol. 2019; 12:1756284819848631.TA

Abstract

Tofacitinib is an oral small molecule directed against the JAK/STAT pathway, blocking the inflammatory cascade. Oral formulation of tofacitinib has recently been approved for the treatment of patients with moderate-severe ulcerative colitis. Its efficacy and safety have been demonstrated in three phase III clinical trials and confirmed by promising real-life data. The purpose of this review is to summarize the available evidence on the efficacy and safety of tofacitinib and to define its role and position in the treatment algorithms for patients with ulcerative colitis.

Authors+Show Affiliations

Department of Biomedical Sciences, Humanitas University, Milan, Italy.Department of Biomedical Sciences, Humanitas University, Milan, Italy.Department of Biomedical Sciences, Humanitas University, Milan, Italy Department of Gastroenterology, Humanitas Clinical and Research Center, Milan, Italy.Department of Hepato-Gastroenterology and Inserm U954, University of Lorraine, Vandoeuvre-lès-Nancy, France.Department of Gastroenterology, Humanitas Clinical and Research Center, Milan, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31205486

Citation

D'Amico, Ferdinando, et al. "Tofacitinib in the Treatment of Ulcerative Colitis: Efficacy and Safety From Clinical Trials to Real-world Experience." Therapeutic Advances in Gastroenterology, vol. 12, 2019, p. 1756284819848631.
D'Amico F, Parigi TL, Fiorino G, et al. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol. 2019;12:1756284819848631.
D'Amico, F., Parigi, T. L., Fiorino, G., Peyrin-Biroulet, L., & Danese, S. (2019). Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therapeutic Advances in Gastroenterology, 12, 1756284819848631. https://doi.org/10.1177/1756284819848631
D'Amico F, et al. Tofacitinib in the Treatment of Ulcerative Colitis: Efficacy and Safety From Clinical Trials to Real-world Experience. Therap Adv Gastroenterol. 2019;12:1756284819848631. PubMed PMID: 31205486.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. AU - D'Amico,Ferdinando, AU - Parigi,Tommaso Lorenzo, AU - Fiorino,Gionata, AU - Peyrin-Biroulet,Laurent, AU - Danese,Silvio, Y1 - 2019/05/16/ PY - 2019/02/22/received PY - 2019/04/15/accepted PY - 2019/6/18/entrez PY - 2019/6/18/pubmed PY - 2019/6/18/medline KW - real-world experience KW - tofacitinib KW - ulcerative colitis SP - 1756284819848631 EP - 1756284819848631 JF - Therapeutic advances in gastroenterology JO - Therap Adv Gastroenterol VL - 12 N2 - Tofacitinib is an oral small molecule directed against the JAK/STAT pathway, blocking the inflammatory cascade. Oral formulation of tofacitinib has recently been approved for the treatment of patients with moderate-severe ulcerative colitis. Its efficacy and safety have been demonstrated in three phase III clinical trials and confirmed by promising real-life data. The purpose of this review is to summarize the available evidence on the efficacy and safety of tofacitinib and to define its role and position in the treatment algorithms for patients with ulcerative colitis. SN - 1756-283X UR - https://www.unboundmedicine.com/medline/citation/31205486/full_citation L2 - https://journals.sagepub.com/doi/10.1177/1756284819848631?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.